Your browser is no longer supported. Please, upgrade your browser.
XLO [NASD]
Xilio Therapeutics, Inc.
Index- P/E- EPS (ttm)-107.16 Insider Own2.70% Shs Outstand30.10M Perf Week-2.44%
Market Cap409.96M Forward P/E- EPS next Y-3.19 Insider Trans254.40% Shs Float23.61M Perf Month17.31%
Income- PEG- EPS next Q-1.17 Inst Own55.20% Short Float1.70% Perf Quarter-
Sales- P/S- EPS this Y-219.00% Inst Trans- Short Ratio2.54 Perf Half Y-
Book/sh-175.18 P/B- EPS next Y41.20% ROA- Target Price34.75 Perf Year-
Cash/sh3.32 P/C4.11 EPS next 5Y- ROE- 52W Range8.52 - 27.95 Perf YTD-14.88%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-51.27% Beta-
Dividend %- Quick Ratio8.20 Sales past 5Y- Gross Margin- 52W Low59.77% ATR1.57
Employees69 Current Ratio8.20 Sales Q/Q- Oper. Margin- RSI (14)45.70 Volatility11.77% 10.64%
OptionableNo Debt/Eq- EPS Q/Q-41.20% Profit Margin- Rel Volume0.11 Prev Close15.37
ShortableYes LT Debt/Eq- EarningsDec 02 BMO Payout- Avg Volume157.59K Price13.62
Recom1.70 SMA20-9.47% SMA50-14.73% SMA200-17.73% Volume17,877 Change-11.39%
Jan-10-22Initiated H.C. Wainwright Buy $36
Nov-16-21Initiated Raymond James Outperform $31
Nov-16-21Initiated Morgan Stanley Overweight $32
Nov-16-21Initiated Guggenheim Buy $40
Nov-16-21Initiated Cowen Outperform
Jan-20-22 07:30AM  
Jan-06-22 07:30AM  
Dec-02-21 07:30AM  
Nov-12-21 07:00AM  
Oct-27-21 07:45AM  
Oct-26-21 04:05PM  
Xilio Therapeutics, Inc., a biotechnology company, designs immunotherapies to improve the immune system for cancer patients. Its checkpoint inhibitor programs include XTX101, is a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1 clinical trials in patients with solid tumors; and cytokine programs comprise XTX202, XTX301, and XTX401, which are modified form of IL-2 that is masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Bain Capital Life Sciences Inv10% OwnerDec 10Buy9.6525,000241,2022,805,413Dec 10 08:33 PM
Bain Capital Life Sciences Inv10% OwnerDec 09Buy9.844,01139,4852,780,413Dec 10 08:33 PM
Bain Capital Life Sciences Inv10% OwnerDec 08Buy9.6213,458129,4742,776,402Dec 10 08:33 PM
RiverVest Venture Fund IV, L.P10% OwnerOct 26Buy16.00250,0004,000,0001,441,444Oct 26 05:30 PM
Rock Springs Capital Managemen10% OwnerOct 26Buy16.00500,0008,000,0001,256,472Oct 26 05:04 PM
BAY CITY CAPITAL LLC10% OwnerOct 26Buy16.00312,5005,000,0001,129,490Oct 26 05:02 PM
Atlas Venture Fund XI, L.P.10% OwnerOct 26Buy16.00187,5003,000,000735,942Oct 26 05:01 PM
Flynn James EPossible Member of 10% GroupOct 26Buy16.00775,00012,400,0001,143,972Oct 28 07:15 PM